The results (Figure 7B) showed that approximately 5% of RGD-GHK and 0.5% of GHK were detected in the receptor cell, and 5% of RGD-GHK and 2.7% of GHK were detected in the skin
This study is the first to our knowledge to show the promising effects of MT-II treatment in an environmental, non-genetic, mouse model of autism resulting in rescue of social deficits
examined 11 studies involving patients over the age of 65 receiving GLP-1 receptor agonist treatments
Always consult with a healthcare professional before making changes to your medication regimen
Despite initially promising results, SAR425899 has been discontinued after phase 2 trials showed treatment related gastrointestinal disorders (NCT03437720)
Eli Lilly's Cease-and-Desist letter only reinforces and reinvigorates OrderlyMeds' mission to provide patients with tailored healthcare solutions, access, and choice